A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

NCT05525715 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: 2mg QY201 tablets or 2mg QY201 placebo,BID
DRUG: 5mg QY201 tablets or 5mg QY201 placebo,BID
DRUG: 10mg QY201 tablets or 10mg QY201 placebo,QD
DRUG: 10mg QY201 tablets or 10mg QY201 placebo,BID
DRUG: 15mg QY201 tablets or 15mg QY201 placebo,BID
DRUG: 20mg QY201 tablets or 20mg QY201 placebo,BID
DRUG: 5mg QY201 tablets，BID
DRUG: 10mg QY201 tablets，BID
DRUG: 20mg QY201 tablets，BID
DRUG: QY201 placebo，BID

Sponsor

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.